Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy: Laboratory investigation

Journal of Neurosurgery: Pediatrics

Volumn 1, Issue 4, 2008, Pages 305-313

  Kasuga, Chinatsu ^a,c   Nakahara, Yukiko ^a   Ueda, Shigeo ^a   Hawkins, Cynthia ^a   Taylor, Michael D ^a   Smith, Christian A ^a   Rutka, James T ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; GAGE; MAGE; Medulloblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CASPASE 3; CISPLATIN; ETOPOSIDE; MELANOMA ANTIGEN 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL LINE; CYTOTOXICITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; NEOPLASM PROTEINS;

EID: 42149157253     PISSN: 19330707     EISSN: 19330715     Source Type: Journal    
DOI: 10.3171/PED/2008/1/4/305     Document Type: Article

References (60)

1. Barker PA, Salehi A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67:705-712, 2002
2. Bertram J, Palfner K, Hiddemann W, Kneba M: Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 9:311-317, 1998
3. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, et al: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175, 1995
4. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G: The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 6:1559-1564, 1997
5. Cilensek ZM, Yehiely F, Kular RK, Deiss LP: A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 1:380-387, 2002
6. De Bortoli M, Castellino RC, Lu XY, Deyo J, Sturla LM, Adesina AM, et al: Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer 6:223, 2006
7. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360-369, 1994
8. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al: Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 3:9, 2003
9. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, et al: Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 60:1654-1662, 2000
10. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, et al: Overexpression of MAGE/GAGE genes in paclitaxel/ doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778-2785, 2003
11. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22:994-998, 2004
12. Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, et al: A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 91:1800-1807, 2004
13. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433, 2001
14. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11:8055-8062, 2005
15. Gurney JG, Kadan-Lottick N: Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160-166, 2001
16. Heyting C: Synaptonemal complexes: structure and function. Curr Opin Cell Biol 8:389-396, 1996
17. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270-5282, 2004
18. Jacobsen PF, Jenkyn DJ, Papadimitriou JM: Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 44:472-485, 1985
19. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, Walsh GL, et al: Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61:7959-7963, 2001
20. Janssen BL, van de Locht LT, Fourkour A, de Smet C, Mensink EJ, van Muijen GN, et al: Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique. Melanoma Res 9:213-222, 1999
21. Jordan BW, Dinev D, LeMellay V, Troppmair J, Gotz R, Wixler L, et al: Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J Biol Chem 276:39985-39989, 2001
22. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106:167-174, 2005
23. Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langston JW, Mulhern RK, et al: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 8:330-336, 1990
24. Lim FL, Soulez M, Koczan D, Thiesen HJ, Knight JC: A KRA-Brelated domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17:2013-2018, 1998
25. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic oligonucleotide arrays. Nat Genet 21 (1 Suppl): 20-24, 1999
26. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, et al: Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 101 (Suppl 2):14631-14638, 2004
27. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143-152, 2001
28. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y: An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 277:34287-34294, 2002
29. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, et al: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278:10668-10674, 2003
30. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202-4208, 2006
31. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690-698, 1994
32. Park JH, Kong GH, Lee SW: hMAGE-A1 overexpression reduces TNF-alpha cytotoxicity in ME-180 cells. Mol Cells 14:122-129, 2002
33. Park PC, Taylor MD, Mainprize TG, Becker LE, Ho M, Dura WT, et al: Transcriptional profiling of medulloblastoma in children. J Neurosurg 99:534-541, 2003
34. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
35. Põld M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR: Identification of a new, unorthodox member of the MAGE gene family. Genomics 59:161-167, 1999
36. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al: Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 415:436-442, 2002
37. Rimoldi D, Romero P, Carrel S: The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumor cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 54:527-528, 1993
38. Sahin U, Koslowski M, Türeci O, Eberle T, Zwick C, Romeike B, et al: Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6:3916-3922, 2000
39. Sakata M: Expression of MAGE gene family in lung cancers. Kurume Med J 43:55-61, 1996
40. Sakurai T, Itoh K, Higashitsuji H, Nagao T, Nonoguchi K, Chiba T, et al: A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem 279:15505-15514, 2004
41. Salehi AH, Roux PP, Kubu CJ, Zeindler C, Bhakar A, Tannis LL, et al: NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron 27:279-288, 2000
42. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335-341, 1999
43. Scheurlen W, Sörensen N, Roggendorf W, Kühl J: Molecular analysis of medulloblastomas occurring simultaneously in monozygotic twins. Eur J Pediatr 155:880-884, 1996
44. Silber JR, Bobola MS, Ewers TG, Muramoto M, Berger MS: O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1, 3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines. Oncol Res 4:241-248, 1992
45. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625, 2005
46. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197:155-162, 2002
47. Stein WD, Litman T, Fojo T, Bates SE: A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64:2805-2816, 2004
48. Stratton MR, Darling J, Pilkington GJ, Lantos PL, Reeves BR, Cooper CS: Characterization of the human cell line TE671. Carcinogenesis 10:899-905, 1989
49. Szakács G, Gottesman MM: Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv 4:323-325, 2004
50. Tamura K, Shimizu K, Yamada M, Okamoto Y, Matsui Y, Park KC, et al: Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. Cancer Res 49:5380-5384, 1989
51. Taniura H, Matsumoto K, Yoshikawa K: Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem 274:16242-16248, 1999
52. Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95:5211-5216, 1998
53. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698, 1995
54. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991
55. Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, et al: Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169:1102-1109, 2002
56. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-29-deoxycytidine. Cancer Res 54:1766-1771, 1994
57. Wen CJ, Xue B, Qin WX, Yu M, Zhang MY, Zhao DH, et al: hNRAGE, a human neurotrophin receptor interacting MAGE homologue, regulates p53 transcriptional activity and inhibits cell proliferation. FEBS Lett 564:171-176, 2004
58. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, et al: Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127:267-275, 2007
59. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
60. Zhou Q, He Q, Liang LJ: Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 9:2450-2454, 2003